Skip to main content

Animations

MJFF Publications

1141 - 1150 of 6466 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2023
  • 2025
  • 2024
  • 2022
  • 2023
  • Summary Details
    OPEN
    Title: The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2022.1036068
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential
    Journal Name: Communications Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s42003-022-03965-x
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Integrating multi-omics summary data using a Mendelian randomization framework
    Journal Name: Briefings in Bioinformatics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1093/bib/bbac376
    Citation Count: 30
  • Summary Details
    OPEN
    Title: CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers
    Journal Name: Journal of Neurology, Neurosurgery & Psychiatry
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1136/jnnp-2022-330052
    Citation Count: 22
  • Summary Details
    OPEN
    Title: Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites
    Journal Name: Science
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/science.abm3233
    Citation Count: 233
  • Summary Details
    OPEN
    Title: A progression analysis of motor features in Parkinson's disease based on the mapper algorithm
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2023.1047017
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.98775.3
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Additional feedforward mechanism of Parkin activation via binding of phospho-UBL and RING0 in trans
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.96699.3
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Temporal order of clinical and biomarker changes in familial frontotemporal dementia
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41591-022-01942-9
    Citation Count: 138
  • Summary Details
    OPEN
    Title: Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study
    Journal Name: Biomedicines
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/biomedicines11020573
    Citation Count: 3
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.